Multiple myeloma (MM) is more recently being recognized as a heterogeneous group of disease with variability in outcomes based on specific clinical and biologic predictors. MM patients can be broadly categorized into standard, intermediate and high risk for disease relapse, morbidity and mortality. The high-risk features include patient-specific factors such as old age, poor performance status and comorbidities; clinical features such as primary plasma cell leukemia and extramedullary disease; disease-specific biologic features such as deletion 17p, t(4;14) and high-risk gene expression profiling signatures. The current paper reviews the available data on best therapeutic approaches for high-risk MM.
INTRODUCTION
The survival of multiple myeloma (MM) patients has significantly improved over the past two decades, first through the introduction of autologous stem cell transplant (ASCT), and more recently due to the use of proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide). However, this improvement has not been uniform, with some patients achieving long-term remissions being probably already cured, whereas others having dismal prognosis with a very short survival. This heterogeneity is related to either host features or specific characteristics of the tumor. A stable treatment paradigm for the management of MM has allowed for analysis of discrete variables that predict response and survival. Over the past 20 years, cytogenetics and International Staging System (ISS) are the two well-studied variables that have been primarily used to assign high-risk disease, a subset that constitutes a sizeable percentage of all patients and presents an unmet therapeutic challenge. By defining high-risk biologic and clinical variables, a strong case can be made for a more precise counseling of the patients regarding their disease prognosis, and for treating patients with investigational agents within the framework of risk-adapted clinical trials. In this paper, we review updated understanding of the most relevant factors that define high-risk subtype of MM represented by a survival of less than 3 years. In addition, we discuss treatment strategies that can be offered to these patients and how initial evaluation can be used to inform the choice of treatment.
FACTORS THAT DETERMINE HIGH-RISK DISEASE
Patient-specific factors Similar to other hematologic malignancies, in MM, patient-specific variables have been long recognized to influence prognosis. There are three main patient characteristics that influence survival: age, comorbidities (renal failure, cardiac failure and so on) and frailty. It is well known that age is an adverse prognostic factor, probably due to an increased treatment-related toxicity and worse biology associated with increasing age. In the largest study comparing survival in 1689 patients aged younger than 50 years and 8860 patients aged 50 years or older from the time when immunomodulatory agents and proteasome inhibitors were not easily available, it was shown that younger patients had significantly longer age-adjusted survival both after conventional and highdose therapy (5.4 and 7.5 years, respectively) compared with older patients (3.7 and 5.7 years, respectively). 1 Lower ISS stage and other favorable clinical prognostic features accounted for the significantly improved outcome of young patients in this study. Other studies such as the data of International Blood and Bone Marrow Registry with an age cutoff of 60 years, 2 and data from Arkansas group with an age cutoff of 65 years, 3 in contrast, did not reveal significant differences in survival between younger and older patients, possibly attributed to selection of particularly fit elderly patients and/or shorter follow-up included in these studies. In a retrospectively analyzed data from 1435 elderly patients enrolled in 4 European phase III trials including thalidomide and/or bortezomib, it was found that age 75 years or over or renal failure at presentation, occurrence of infections and cardiac or gastrointestinal adverse events negatively affected survival. 4 More recently, it has become evident that the adverse prognosis of elderly patients is not related to the chronological age but to the associated physical and cognitive functional limitation, comorbidities and geriatric syndromes. Accordingly, geriatric assessment (GA) has become increasingly important for elderly patients. The International Myeloma Working Group, through a pooled analysis of 869 newly diagnosed elderly patient data from three prospective international trials, proposed the use of a simplified GA score. 5 Using this scoring system (range 0-5), based on age, comorbidities, cognitive and physical conditions, three groups were identified: fit (score = 0, 39%); intermediate fitness (score = 1, 31%), and frail (score ⩾ 2, 30%). The frail patients had a significantly shorter 3-year overall survival (OS) (57%) as compared with intermediate fitness (76%) and fit patients (84%).
Moreover, the frailty profile emerged as an independent prognostic factor for increased risk of death, progression, non-hematologic adverse events and treatment discontinuation in multivariate analysis, regardless of staging, chromosomal abnormalities and treatment administered. 5 Rather than relying on chronologic age, performance status and physician's clinical judgment, the GA score is a more objective predictor of clinical outcomes that may be adopted as a new standard to evaluate frailty in older patients and to allow more precise cross-trial comparisons. It remains to be investigated whether the GA score can be utilized to tailor treatment decisions for elderly patients.
Disease-specific factors
Disease-related risk factors are mainly represented by biomarkers specific to cytogenetic and molecular features of tumor that are associated with outcome. In addition, there are many factors related to overall disease burden, including clinical stage, high serum lactate dehydrogenase (LDH), high number of circulating plasma cells (CPCs), extramedullary disease (EMD) and organ impairment that are associated with poor prognosis. Importantly, regardless of known risk factors, resistance to therapy is the major cause of treatment failure. Early relapse, refractory disease and MM characterized by suboptimal response, or with minimal residual disease after treatment also define the high-risk group. Cytogenetics: largely based on retrospective studies, a pattern of recurrent myeloma-specific cytogenetic abnormalities was first identified as important in differentiating patients with respect to response to treatment. Table 1 summarizes the most relevant cytogenetic abnormalities that influence survival in MM patients. These abnormalities are evenly distributed across all age groups and do not necessarily cluster among older or younger patients. Moreover, distinguishing MM by the dominant clonal cytogenetic pattern does not address how these abnormalities occur or why they define disease behavior better than histochemical stains or immunophenotype. Nevertheless, the prognostic value of pretreatment cytogenetics is of sufficient importance to recommend that these studies be incorporated into the hematopathology work-up of all newly diagnosed MM patients. In clinical practice, we recommend testing of cytogenetic abnormalities on bone marrow aspirate by fluorescent in situ hybridization (FISH) in purified plasma cells or in combination with immunofluorescent detection of light-chain-restricted plasma cells (Cig-FISH). In addition, if possible, standard karyotyping and evaluation for plasma cell gene expression profiling using the US Food and Drug Administration-approved diagnostic test such as MyPRS could be of value. In 2009, the International Myeloma Working Group formulated a consensus that a bare minimum of FISH panel testing t(4;14), t(14;16) and del(17p) should be done for all patients at diagnosis, as these aberrations can define a patient with high-risk disease. 6 Since this recommendation, additional data have suggested that FISH analysis for +1q and t (14;20) should also be considered to further aid in risk stratification. 7 Regarding the two major high-risk abnormalities, that is, t(4;14) and del(17p), studies have consistently shown that the outcome of patients with del(17p) is uniformly poor, whereas for the t(4;14) there is some disagreement. Patients with t(4;14) treated with either conventional or high-dose chemotherapy typically display shorter event-free survival and OS. [8] [9] [10] However, accumulating evidence supports the notion that outcome of patients with t(4;14) is not uniformly poor, and certain heterogeneity is observed. The French group has discriminated a subgroup of t(4;14) patients (~45%) with both low β2-microglobulin and high hemoglobin levels at diagnosis, which display a prolonged survival after tandem transplant. 7 The Mayo clinic group showed that high-risk abnormalities lose part of their prognostic value when associated with hyperdiploidy, specifically trisomies of the odd chromosomes. 11 However, this has not been reproduced by the French group. 12 More recently, utilizing an unbiased technique, that is, single-nucleotide polymorphism array that allows the identification of all copy-number changes through the genome, the French group showed that heterogeneity among t(4;14) patients can be explained by several other concomitant cytogenetic abnormalities found to be independently associated with progression or death. 12 Of other IgH translocations, the association of t(14;16) with poor prognosis has not been well corroborated because of its low frequency. According to Mayo Clinic data, t(14;16) is linked to poor outcome in the context of conventional chemotherapy. 11 However, controversial results have been reported using ASCT. Whereas a study from the MRC group showed a significantly shorter survival among patients with t(14;16) treated with ASCT, 13 the Intergroupe Francophone du Myelome (IFM) group did not confirm the poor prognostic value of t (14;16) in patients who received a tandem ASCT. 14 In contrast, del (17p) (with deletion of TP53 gene) is one of the most, if not the most, adverse prognostic factor in MM. The IFM has postulated that higher the proportion of plasma cells bearing 17p deletions the shorter the survival, with very poor outcome for patients displaying del(17p) in at least 70% of the plasma cells. 15 On the other hand, in the experience of the Spanish myeloma group (GEM) lower cutoff values (420% PC with del17p, which qualified for positivity) was also associated with short survival. 8, 16 In the recent IFM study including patients with del(17p) in at least 60% of the plasma cells, the uniformly poor outcome of the subgroup was explained owing to lack of significant other specific cytogenetic factors in these patients, which were independently associated with outcomes. 12 Several studies have shown that 1q gain confers a poor prognosis, although its role as an independent factor is controversial. In addition, the IFM group has reported that 1p deletion affecting FAF1 and CDKN2C is a major independent prognostic factor associated with short progression-free survival (PFS) and OS. 13, 17 Moreover, the presence of complex as well as non-hyperdiploid karyotypes also predicts treatment failure. In contrast, hyperdiploid tumors with multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 tend to have a favorable prognosis, 18 and so do the patients with hyperdiploid DNA cell content (defined by flow cytometry). 18, 19 According to 2014 International Myeloma Working Group recommendation, the term 'high-risk MM' should include those patients with at least one of the following features: del(17p), t(4;14) or t(14;16), detected by FISH analysis. 20 Hypodiploidy defined by karyotyping is also used by the Mayo Clinic to define high-risk patients. It is important to consider that there is strong association among cytogenetic abnormalities, for instance, t(4;14), 1q gains and/or 17p deletions may be associated, and this has an important influence on survival. Thus, the UK group has shown that in patients in whom these two or three cytogenetic abnormalities coexist, the survival is very poor with a median of 24 and 9 months, respectively. 7 In other words, they are able to identify an ultra-high-risk subgroup, with survivals significantly shorter as compared with the 42 and 61 months for those patients having just one or no genetic lesions. 7 Accordingly, a prognostic model in MM based on the frequently associated genetic lesions can been proposed: a favorable risk group with no adverse FISH lesions, an intermediate group with t(4;14) and low β-2-microglobulin and normal hemoglobin level; a high-risk group with one adverse genetic lesion -t(4;14), t(14;16) or t(14;20); 17p deletion or 1q gain and an ultra-high-risk group with more than one adverse genetic lesion. ISS: the first staging system for MM, developed by Durie and Salmon in 1975, 21 although still useful, proves less reliable for modern day prognosis. ISS is based on the prognostic factors of serum β2-microglobulin and serum albumin, which reflect disease burden plus renal function and patient 'fitness,' respectively. 22 On the basis of this system, ISS stage III defined by serum β2-microglobulin ⩾ 5.5 mg/l represents a high-risk group with a median survival of 29 months. Although ISS remains prognostic within clinical trials, this system does not take into account the genetic abnormalities, and it is possible that the integrated ISS-genetics model may be more meaningful for assessing risk on an individual patient basis compared with either parameter alone. In order to improve risk stratification, Avet-Loiseau et al. 23 have combined cytogenetics with clinical stage according to the ISS and LDH. Five percent of the patients showed adverse cytogenetics plus either ISS III or high LDH, and they had a dismal outcome with a median survival of only 19 months. The validity of this staging index has been reproduced in a large series of over 2169 patients coming from Italian, Dutch, French and Spanish trials, and it was confirmed that 7% of all patients corresponded to the high-risk category with an OS at 2 years of 55%. 24 Another similar scoring system was proposed by Cavo and Rosinol 25 by using cytogenetics and advance clinical stage (ISS III) plus failure to achieve a complete response to bortezomib-based induction therapy; patients with score 3, showed a median PFS of 26 months and an OS of 33% at 5 years. Gene expression profiling: has also been used to identify high-risk patients. The Arkansas model based on a 17-gene set was able to identify a high-risk subset with approximately a median OS of 3 year. 26 The French group has also designed a model based on 15 genes that identify 25% of the myeloma population as high risk with an OS of 47% at 3 years. 27 The HOVON/GMMG group generated a prognostic signature of 92 genes confirmed in sets of newly diagnosed and relapsed patients, and were able to identify about 20% patients with OS of less than 2 years in both the transplant-eligible and non-transplant-eligible groups. 28 Plasma cell leukemia (PCL) and CPC: It is a well-known fact that PCL (accounting for 0.6-4% of all cases) characterized by CPC absolute count of 42000/μl or presence of 420% CPC carries a very poor prognosis with median survival measured in months. More recently, we have learnt that presence of CPCs, using a specialized slide-based immunofluorescent test or even better flow cytometry, below the threshold limits diagnostic for PCL, are frequently present in newly diagnosed MM patients (35-87% of the cases). The Mayo Clinic has shown that in patients with standard-risk MM and 4400 CPCs (quantified by flow cytometry), the time to next therapy and OS was significantly reduced: median of 14 and 25 months, respectively. 29 This finding would be in agreement with the well-established poor prognosis of primary PCL with a median OS ranging between 4 and 20 months. 30 Interestingly, the Arkansas group has shown that although the outcome of MM patients has significantly improved with the evolution of Total Therapy (TT) programs (TT1, TT2 and TT3), the same improvement was not observed in patients with primary PCL, with median PFS of 0.8 years and OS of 1.8 years. 31 EMD: presence of EMD, either accompanying newly diagnosed disease or developing with disease progression or relapse, portends a poor prognosis. In the Arkansas experience, the detection of EMD prior to transplant was associated with a short survival, 31% at 5 years as compared with 60% in patients without EMD. 32 The Italian group has confirmed these results, and patients with EMD detected by PET-CT at diagnoses had a significantly shorter PFS as compared with negative cases (25 vs 60% at 4 years, respectively), as well as a shorter OS (65 vs 89% at 4 years). 33 The Spanish Myeloma Group also reproduced that the presence of EMD in transplant candidates patients is associated with a trend to a shorter PFS (22 months vs 33 months, for patients with and without EMD, respectively) and significantly shorter OS (46.7 months vs median not reached). 34 Response to therapy: in addition to all the variables that can be measured at diagnosis and that have been already mentioned, response to frontline therapy represents one of the most important prognostic factors in most hematological malignancies, and MM is not an exception. In the experience of the Spanish Myeloma Group, patients failing to respond to initial therapy (either stable or progressive disease), showed a survival of o 2 years. 35 Moreover, among patients achieving complete response, there is a subgroup of early relapses (unsustained Complete response) with a remission duration of o 6 months. These patients with high risk of early relapse after achieving a complete response can be identified by the presence of high-risk cytogenetics at diagnosis, and with persistent residual disease in the bone marrow obtained after transplant in spite of being in conventional complete response. The median survival of these patients was only 21 months. 35 
REFINING THE DEFINITION OF HIGH-RISK DISEASE
Paralleling the advances in therapeutic options and disease characterization, the risk stratification systems remain in flux and undergo regular updating to include the biomarkers relevant to prognosis, thus querying their potential alone and in combination with others to move the patient to a better or worse risk group. On the basis of our above discussion, we can consider high-risk myeloma as those patients with an expected survival inferior to 3 years, whereas the ultra-high-risk MM would have a survival of o2 years. The latter category can be defined based on the following features: (1) presence of two or more adverse cytogenetic features; (2) one cytogenetic adverse feature plus either high LDH or advance clinical stage (ISS 3) or failure to achieve a complete response with induction; or patients with adverse cytogenetics but that fail to eradicate residual disease;
(3) patients with a high number of CPCs (4400) and (4) finally, patients that fail to respond (less than partial response to an optimized induction therapy), which includes a proteasome inhibitor and an immunomodulatory agent ( Table 2) .
THERAPEUTIC OPTIONS FOR HIGH-RISK MM
While weighing a therapeutic approach for high-risk MM, it is important to appreciate that this is a heterogeneous group of MM with several clinical and biologic markers, and outcomes to any given therapy may be very heterogeneous. It is also very important to distinguish the difference between improving poor prognosis conferred by a given disease marker and overcoming the poor prognostic markers altogether. For example, novel drug 'A' may be able to help improve the median OS of high-risk MM patients with primary PCL from 6 months to 12 months, but fails to elevate the OS to that of standard-risk MM. Thus despite a doubling of OS in months, the novel drug 'A' cannot overcome the poor prognosis of primary PCL. Among the poor prognostic cytogenetic abnormalities, translocation (4;14), deletion 17p and gains of chromosome 1q21 have been perhaps examined more closely during the era of novel agents. 13 Choice of induction and maintenance therapy The concept of high-risk MM has emerged from data using induction treatment with conventional chemotherapy followed by ASCT, showing a 20-50% decrease in OS for high-risk as compared with standard-risk cytogenetics. 10, 36, 37 It is now routine practice in the United States to treat all patients with newly diagnosed MM with novel agents. Thalidomide was the first novel drug to be tested for its efficacy in high-risk patients either as induction (TD, TAD and CTD) or as maintenance therapy, and in both settings high-risk patients did significantly poorer than standard risk. 34, 38, 39 Moreover, studies derived from the UK group (MRC IX intensive, MRC IX non-intensive and MRC IX maintenance) indicate that thalidomide is not superior to conventional chemotherapy in patients with high-risk cytogenetic abnormalities. [39] [40] [41] Accordingly, it could be concluded that thalidomide neither improves nor overcomes the poor prognosis of high-risk patients. Regarding lenalidomide, a small study conducted by Kapoor et al. 42 in newly diagnosed patients showed that high-risk patients display significantly shorter PFS (18 vs 26 months for high vs standard risk, respectively). Perhaps the most interesting information on the role of lenalidomide in high-risk patients derives from the maintenance trial conducted by the IFM group. Chromosomal data were available in 488 patients: 13.3% had t(4;14) and 6.6% del (17p). In patients with t(4;14), maintenance treatment apparently did not affect outcome (PFS: 27 vs 24 months for maintenance vs non maintenance, respectively). By contrast, a clear benefit was observed for maintenance treatment in patients with deletion 17p (PFS: 29 vs 14 months). Nevertheless, it should be noted that these PFS values are clearly inferior to those of the overall series of patients (42 months). Therefore, it could be concluded that lenalidomide maintenance improves the outcome specially in patients with del(17p), but does not completely overcome the poor prognosis of high-risk cytogenetics. 43 There are now strong data that demonstrate the poor prognosis associated with t(4;14) may be improved by the addition of bortezomib as part of induction and consolidation in newly diagnosed transplant-eligible patients. The HOVON-65/GMMG-HD4 phase III trial randomized patients to receive induction therapy with either vincristine-adriamycin-dexamethasone (VAD) or bortezomib-adriamycin-dexamethasone followed by thalidomide maintenance in the VAD arm, and bortezomib maintenance in the bortezomib-adriamycin-dexamethasone arm. 44 The 3-year OS for patients with t(4;14) was far superior in the bortezomib arm (82 vs 55%, P = 0.0003). The HOVON-65/GMMG-HD4 trial also demonstrated OS benefit for del(17p) (83 vs 33%, P o0.0001) in favor of the arm with bortezomib. The IFM 2005-01 trial (bortezomib-dexamethasone vs VAD induction pre-ASCT) also reported an improved outcome for t(4;14) MM on the bortezomib-dexamethasone arm when compared with the VAD arm, but no respite was observed for patients with del(17p). 37 In a metaanalysis of three European trials, Cavo et al. 45 presented compelling data that bortezomib-based ASCT was associated with improved outcome of patients with high risk t(4;14) and del (17p) compared with ASCT not including bortezomib, although the apparent benefits did not completely overcome adverse prognosis of these abnormalities, particularly de(17p).
The management of transplant-ineligible high-risk MM remains a further challenge. Although initially in the VISTA trial 46 (phase III: melphalan-prednisone with or without bortezomib) there was no statistical difference based on cytogenetic features for response and survival in newly diagnosed patients on the bortezomib arm, the number of patients was rather small (n = 26) and longer follow-up showed a trend to inferior survival for high-risk patients. Similarly, in the Spanish GEM-05 phase III trial of bortezomibmelphalan-prednisone vs bortezomib-thalidomide-prednisone induction, followed by bortezomib-thalidomide vs bortezomibprednisone maintenance, PFS and OS were shorter for high-risk MM transplant-ineligible patients. 47 In the lenalidomide-dexamethasone (high vs low dose) trial, the 2 years OS was also significantly shorter for high-risk patients (76 vs 91%). 48 An IFM study including 1095 elderly patients with updated information shows that whatever the treatment, t(4;14) and del(17p) were associated with shorter PFS and OS as compared with patients without these abnormalities. 49 Therefore, first-generation novel agents may have improved, but certainly have not helped in overcoming the poor prognosis of high-risk MM in transplantineligible patients. The SWOG-1211 is the first trial focusing on high-risk MM patients who are transplant ineligible or have deferred ASCT, randomizing patients to bortezomib-lenalidomide-dexamethasone with/without addition of elotuzumab (monoclonal antibody targeting CS1/SLAM7 that is overexpressed on plasma cells). It may provide some guiding posts regarding outcomes in this subgroup in the era of novel agents. 50 
ASCT-single vs tandem
The role of ASCT has been under scrutiny for MM with emergence of targeted therapy, but based on available clinical data this strategy remains a standard of care for eligible patients. Trends of improved survival of certain high-risk subsets have been reported by the Arkansas team in the TT program, where the tandem ASCT approach is preceded by induction and followed by consolidation/ maintenance phases that have more recently included bortezomib. They report that poor risk associated with MS molecular subgroup of patients-comprising FGFR3 gene and/or MMSET gene overexpression correlating with translation t(4;14)-which was observed in TT2 trial (no bortezomib), was overcome by inclusion of bortezomib in TT3A and TT3B trials. 51 It was also observed that the survival benefit for the low p53 gene expression levels (17p deletion) was only associated with gene expression High-risk multiple myeloma profiling defined in low-risk MM patients and not in high-risk patients. 52 This may suggest that not all 17p deletion are alike.
Interestingly, Cavo and Rosino, 25 in a meta-analysis from 3 European phase III trials (606 patients), have shown that patients with high-risk cytogenetics and who failed to achieve Complete response after bortezomib-based induction may do better with tandem ASCT, with a doubling of PFS (42 months vs 21 months, P = 0.004) and 4-year OS (76 vs 33%, P = 0.0001). This advantage was not seen in the bortezomib-arm patients receiving single ASCT. These data would suggest that tandem ASCT may abrogate the negative impact of either t(4;14) or del(17p).
Role of allogeneic stem cell transplant Allogeneic stem cell transplant has been explored for MM in the era of novel drug classes. This strategy is usually considered for a highly select, young/fit patient population. Most available data in the relapsed/refractory setting suggest no appreciable advantage in PFS/OS speaking against the potential graft-vs-MM affect. 53 A prospective phase III trial compared tandem ASCT with single ASCT, followed by a non-myeloabalative allogeneic stem cell transplant. 54 The high-risk group fared similarly on both arms with 3-year PFS of 40% (95% confidence interval (CI), 27-60%) and 33% (95% CI, 22-50%, P = 0.743), and corresponding probabilities of OS were 59% (95% CI, 45-78%) and 67% (95% CI, 54-82%, P = 0.460) after auto-allo and auto-auto, respectively. A retrospective French analysis on patients receiving allogeneic transplant showed a shorter survival for patients with either t(4;14) (3-year OS: 39 vs 52 months) or del(17p) (3-year OS: 34 vs 42 months) compared with patients without these abnormalities, although the differences were not statistically significant. 55 The study by Kroger et al. 56 in 73 newly diagnosed patients (16 with high-risk cytogenetics) who received tandem auto-allo transplants shows similar 5-year PFS (24 vs 30%) and 5-year OS (50 vs 54%) for highand standard-risk patients.
Next-generation novel agents
The data with second-generation novel agents, carfilzomib and pomalidomide, are primarily in the relapsed/refractory MM. In the pivotal phase II trial that led to the approval of carfilzomib, highrisk patients were reported to have similar overall response rate to standard-risk patients (25.8 vs 24.6%, respectively). 57 High-risk patients had a lower depth of response (clinical benefit rate 30.7 vs 40.7%, respectively) and shorter duration of response (5.6 vs 8.3 months, respectively). However, the patients with isolated t(4;14) had a remarkably higher overall response rate 63.6%, with a median PFS of 4.1 months and OS of 15.8 months (similar to standard risk, 4.6 and 19 months), suggesting this group did as well as the standard-risk group. This is perhaps suggestive of a class effect, as bortezomib also benefits the t(4;14) MM. Carfilzomib, however, did not improve the poor outcome of del (17p) either by itself or in combination with other abnormalities. The MM-003 trial (phase III; pomalidomide-low-dose dexamethasone vs high-dose dexamethasone) showed that pomalidomidelow-dose dexamethasone may provide a comparable survival benefit to del(17p) relapsed/refractory MM patients (12.6 months vs 14 months to no deletion 17p). 58 An IFM phase II trial (2010-02) of pomalidomide-low-dose dexamethasone for relapsed/refractory MM with t(4;14) and del(17p) has also demonstrated a similar OS for del(17p) (12 months) as seen in the MM-003 study. 59 A phase I/II trial of carfilzomib-pomalidomide-dexamethasone for relapsed/refractory MM saw no difference between standard-and high-risk cytogenetics in terms of median PFS or OS. 60 It still remains to be seen whether these data can be validated in prospective trials, especially in the newly diagnosed setting.
Treatment recommendations for high-risk MM in 2015 Our proposed definitions for high-risk and ultra-high-risk MM (about 15-20% of newly diagnosed patients) are summarized in Tables 1 and 2 . It is clear from the presented summary of relevant literature that patients with any of the high-risk features have a disease that is less likely to remit with induction chemotherapy, and those whose disease does respond are far more likely to relapse early. Although we can now identify high-risk MM patients during the initial work-up, it may be too early to develop a treatment algorithm based on risk stratification, in the absence of long-term prospectively validated treatment strategies specifically targeting this group of patients. In an effort to provide a practical approach for initial therapy, myeloma experts at Mayo Clinic have published Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) guidelines suggesting more chemotherapy and for longer periods for patients with high-risk disease with the intent of prolonging survival and enhancing quality of life. 61 Although mSMART is a first step in right direction, we need prospective data from well-designed clinical studies targeting high-risk patients with the primary objective of improving survival, before making definitive recommendations for risk-adapted treatment strategies. Therefore, investigational treatment can be considered an appropriate pathway when treating a patient with high-risk features. However, the major question for physicians is to define what constitutes an effective therapy for these patients. We offer here our recommendations based on approved therapies and make proposals regarding the off-label use of the limited therapies available to clinicians managing patients with highrisk MM.
Unless contraindicated, all transplant-eligible high-risk MM patients should be treated with a triple-induction regimen comprising of proteasome inhibitor, immunomodulatory drugs and dexamethasone. At the current time, bortezomib, lenalidomide and thalidomide are approved by the Food and Drug Administration and European Medicines Evaluation Agency for first-line treatment; however, other agents will be approved in the future. It is our practice to start induction therapy typically with a bortezomib-based triplet regimen, and to assess disease response after every cycle with serum protein electrophoresis plus immunofixation and serum-free light chains, and after four cycles to include bone marrow aspirate and biopsy and 24-h urine protein electrophoresis. For patients achieving partial response or better and who continue to be transplant eligible, outside of a clinical trial and according to patient preference, we proceed with mobilization and collection of peripheral blood stem cells. For patients achieving less than partial response, we switch early to a clinical trial or second-generation combinations of proteasome inhibitors (carfilzomib) and immunomodulatory drugs (lenalidomide and pomalidomide) aiming to deepen the quality of response prior to ASCT. In patients, whose disease is primarily refractory, we switch to DPACE-(dexamethasone, cisplatin, adriamycin, cyclophosphamide and etoposide) based combination regimens adding carfilzomib or bortezomib to the DPACE backbone. We usually proceed to early ASCT using high-dose melphalan conditioning. Our approach for early ASCT is based on data regarding improved quality of life and PFS for MM patients in general, irrespective of risk category. Ongoing and future trials of early vs delayed transplant will answer the question of OS benefit in high-risk MM.
After transplant, we have two alternatives: direct maintenance or more intensive consolidation. The first approach would include maintenance with proteasome inhibitor plus immunomodulatory drugs plus low-dose oral corticosteroids until disease progression or unacceptable side effects for our high-risk patients. The second approach would include a tandem ASCT plus consolidation with the same induction scheme, followed by maintenance. Such a strategy should be considered for and discussed with the fit, young t(4;14) MM patients in detail, in light of the available evidence that tandem ASCT with bortezomib-based induction and maintenance may overcome the unfavorable prognosis of t(4;14) specifically after failure to achieve Complete response after bortezomib-based induction. More data are required to address whether a second transplantation at the time of relapse would perform equally well in these patients, avoiding unnecessary potential toxicity of a sequential ASCT that could later be used as salvage therapy. Similarly, we do not routinely recommend sequential reduced intensity allogeneic transplant after ASCT, given that transplant-related mortality offsets the potential clinical benefit.
For transplantation-ineligible fit patients, at present there are still no combinations able to completely overcome the poor prognosis of high-risk features so formal recommendations are not possible. In the United States, we typically favor bortezomibbased triplet (cyclophosphamide-bortezomib-dexamethasone or lenalidomide-bortezomib-dexamethasone) combination with dose-attenuated therapy until disease progression or unacceptable side effects. In frail patients with comorbidities, lenalidomide and low-dose dexamethasone is commonly used. The ongoing SWOG-1211 clinical trial is attempting to establish guideposts for the optimal regimen for this patient population. In European countries, melphalan-based regimens, such as VMP, are commonly used as part of induction, and in the high-risk population we recommend the addition of Len-dex either in a sequential or alternating scheme, based on the results of the GEM2010 trial.
CONCLUSION
All high-risk MM patients should be encouraged to participate in clinical trials exploring novel agents and novel treatment strategies. The emergence of monoclonal antibodies (anti-CS1, anti-CD38, anti-CD138 and so on), along with novel drug classes such as MDM2 inhibitors, KSP inhibitors, XPO-1 inhibitors and FGFR3 inhibitors, affords us the opportunity to combine these new agents with established novel agent regimens especially in the high-risk MM patient population. The data on pomalidomide for relapsing patients with del(17p) need to be confirmed in newly diagnosed patients, but if the benefit persists in this poor prognostic subset, this drug will be incorporated for the treatment of del(17p) patients. Specific trials targeting high-risk MM are enrolling or will be enrolling patients on the basis of specific disease-related or clinical high-risk features. In this regard, it would be very interesting to see the results of the BMT-CTN 0702 three-arm, randomized phase III trial (of single ASCT +lenalidomide maintenance vs single ASCT+RVD consolidation +lenalidomide maintenance vs tandem ASCT+lenalidomide maintenance) to appreciate the benefit of translocation (4;14) high-risk MM. The results of the SWOG-1211 may help shed light to optimal first-line therapy for ASCT-ineligible/ASCT-deferred high-risk MM patients. For those of us committed to improving the outcome of high-risk MM, it is crucial to design and enroll patients on clinical trials that define the optimal timing and sequence of therapy integrating novel agents and ASCT across different risk groups.
